Topic: Health

Researchers at Washington University School of Medicine in St. Louis have developed a new compound that protects the liver after intestinal surgery and improves nutrient absorption.

Surgeons often remove damaged tissue from the small intestine, but this can lead to serious liver problems. Up to 15% of patients develop long-term damage or even liver failure that may require a transplant. A team at Washington University School of Medicine has developed a new compound called WUSTL0717 that may help prevent or treat these complications.

The researchers tested the drug in mice and found it protected the liver from fibrosis, a buildup of scar tissue that interferes with normal function. The treated mice also gained more weight compared to untreated mice after surgery. This is important because patients who undergo small bowel resection often struggle to absorb nutrients effectively, leading to severe weight loss.

The team's goal is to develop a therapeutic drug that preserves liver function and reduces the need for liver transplants in people who've undergone small bowel surgery.

Why It Matters

This new compound could improve the lives of patients who undergo intestinal surgery. It may also help reduce the number of liver transplants needed, which can be a life-saving but complex procedure.

Key Facts

• The new compound WUSTL0717 was developed by researchers at Washington University School of Medicine in St. Louis.
• Up to 15% of patients who undergo small bowel resection develop long-term liver damage or failure.
• The compound protects the liver from fibrosis and improves nutrient absorption after surgery.

Key Terms

Fibrosis

A buildup of scar tissue that interferes with normal function

Implications

This new compound could improve the lives of patients who undergo intestinal surgery. It may also help reduce the number of liver transplants needed, which can be a life-saving but complex procedure.